Friday, May 9, 2025
5/9/2025
The Role of 17β-Estradiol in Delirium - ABSTRACT Delirium is frequently precipitated by urinary tract infection (UTI), a condition that disproportionately affects older women and contributes to increased mortality, prolonged length of stay, and accelerated long-term cognitive decline. Existing treatments for delirium center largely on treatment of the precipitating cause, modification of environmental contributors, and avoidance of deliriogenic medications; however, do not address the underlying pathobiology of the condition. We have developed a novel mouse model of UTI-induced delirium and generated compelling preliminary data that demonstrate a potential role for exogenously administered 17β-estradiol in mitigating UTI-induced delirium. These findings may explain, at least in part, why older women, who after menopause have reduced levels of 17β-estradiol, are particularly susceptible to developing delirium. In this R21 application, we propose to use our novel mouse model of urinary tract infection- induced delirium, oophorectomized mice, state-of-the-art behavioral testing, and genetically modified mice to determine whether 17β-estradiol ameliorates the structural and functional phenotypes of delirium via the G protein-coupled estrogen receptor 1. Given the lack of evidence-based pharmacological treatments for delirium, the findings from this research could have widespread clinical implications, including providing novel pre-clinical justification for clinical trials using a short-term application of an existing drug, 17β-estradiol, to ameliorate UTI- induced delirium and quality of life for millions of older women around the world.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).